Aside from BACE2 inhibition, the only other significant off-target (non-BACE1) activity of verubecestat is the inhibition of the hERG channel which is a common cause of QTC prolongation and cardiac arrhythmias [13]. This evidence concerns the gene BACE2 and chronic obstructive pulmonary disease.